PHARMACOTHERAPY: Biosimilar switching — “To set a form upon desired change”

    loading  Checking for direct PDF access through Ovid


The highly anticipated NOR-SWITCH trial results provide valuable information for patients and physicians concerned about the effects of switching between a biologic agent and a biosimilar product. However, the possibility of frequent switches, potentially involving more than one biosimilar, raises more questions.

Refers to Jørgensen, K. K. et al. Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): a 52-week, randomised, double-blind, non-inferiority trial. Lancet–6736(17)30068–5 (2017)

Related Topics

    loading  Loading Related Articles